In fact, gene set enrichment analysis of mutant p53 identified a gene signature highly enriched in targets of the MYC transcription factor that were downregulated in head and neck squamous cell carcinoma (HNSCC) by treatment with a PI3 kinase inhibitor. The gene discussed is MYC; the disease is head and neck squamous cell carcinoma.